|
TOP NEWS
ENFORCEMENT & COMPLIANCE
LITIGATION
Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict
By Bryan Koenig
Takeda Pharmaceuticals battled with a class of health plans over whether a Massachusetts federal jury's $885 million antitrust verdict against the drugmaker for conspiring to delay generic competition to anticonstipation drug Amitiza should be reduced by rebates the drugmaker paid and Medicare subsidies that reduced the health plans' costs.
2 documents attached |
Read full article »
| Save to favorites »
Glenmark Pharma Hit With Safety Suit After Carvedilol Recalls
By Craig Clough
Glenmark Pharmaceuticals' generic drug carvedilol, used to treat high blood pressure and congestive heart failure, was misrepresented as therapeutically equivalent to the brand-name drug Coreg but contained undisclosed nitrosamine impurities that changed its strength, quality and safety profile, according to a proposed class action filed Tuesday in Washington federal court.
Complaint attached |
Read full article »
| Save to favorites »
DEALS
PEOPLE
EXPERT ANALYSIS
LEGAL INDUSTRY
|